Alzheimer's Benefits May Continue After Donanemab Treatment Ends, Data Suggest

(MedPage Today) — New data suggested that donanemab (Kisunla) sustained long-term benefits after a limited dosing period in a subgroup of people with early symptomatic Alzheimer’s disease.
Early Alzheimer’s patients who completed their course…

Source link : https://www.medpagetoday.com/meetingcoverage/ctad/118877

Author :

Publish date : 2025-12-07 19:18:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Alzheimer’s Benefits May Continue After Donanemab Treatment Ends, Data Suggest

Hematocrit, Phlebotomy Benefits Seen With Rusfertide in PV

‘This Would Be a Hugely Important Finding’: What We Heard This Week

Related Posts

Parental Obesity Before Pregnancy Linked to Kids’ Chronic Liver Disease Risk

States Sue Trump Admin Over Changes to Childhood Vaccine Recommendations

FDA Approves a Balloon That Patients Swallow to Lose Weight

More Residency Slots Needed in Rural Areas, Lawmakers and Health Experts Say

As Measles Cases Pass 1,000 for the Year, Experts Urge Vaccination

Semaglutide Not Linked to Depression Symptoms in People With HIV

Parental Obesity Before Pregnancy Linked to Kids’ Chronic Liver Disease Risk

States Sue Trump Admin Over Changes to Childhood Vaccine Recommendations

FDA Approves a Balloon That Patients Swallow to Lose Weight

More Residency Slots Needed in Rural Areas, Lawmakers and Health Experts Say

As Measles Cases Pass 1,000 for the Year, Experts Urge Vaccination

Semaglutide Not Linked to Depression Symptoms in People With HIV

Price Controls ‘Inevitable’ in U.S. Healthcare, Economist Says

Too Much Weight Loss With Retatrutide? Transgender Doc Sued; Ice Age Growth Disorder

Categories

Archives